genmab
announces
phase
study
evaluating
epcoritamab
patients
relapsed
refractory
diffuse
large
lymphoma
company
announcement
first
phase
study
epcoritamab
part
broad
clinical
development
plan
abbvie
diffuse
large
lymphoma
common
form
lymphoma
worldwide
copenhagen
denmark
november
genmab
nasdaq
gmab
announced
today
initiate
phase
study
epcoritamab
diffuse
large
lymphoma
dlbcl
study
evaluate
efficacy
safety
subcutaneous
epcoritamab
antibody
designed
recognize
bind
versus
investigators
choice
chemotherapy
regimen
either
bendamustine
rituximab
gemcitabine
oxaliplatin
rituximab
patients
relapsed
refractory
dlbcl
epcoritamab
genmab
abbvie
dlbcl
aggressive
common
form
lymphoma
worldwide
dlbcl
patients
expected
die
disease
within
five
years
prevalence
rates
expected
increase
driven
growth
aging
populations
collaboration
abbvie
planned
broad
expansive
accelerated
epcoritamab
clinical
development
plan
maximize
potential
promising
bispecific
antibody
ultimate
goal
bringing
new
differentiated
treatment
options
soon
possible
patients
look
forward
data
first
phase
trial
especially
relapsed
refractory
dlbcl
patients
remains
area
high
unmet
medical
need
said
jan
van
de
winkel
chief
executive
officer
genmab
study
phase
randomized
study
include
approximately
patients
relapsed
refractory
dlbcl
failed
ineligible
autologous
stem
cell
transplant
asct
patients
randomized
receive
either
subcutaneous
epcoritamab
one
two
chemotherapy
regimens
per
investigator
choice
either
rituximab
gemcitabine
oxaliplatin
bendamustine
rituximab
br
primary
endpoint
study
overall
survival
diffuse
large
lymphoma
dlbcl
common
type
lymphoma
nhl
united
states
worldwide
average
age
diagnosis
aggressive
form
nhl
relative
survival
rates
approximately
relative
survival
rates
approximately
prevalence
anticipated
increase
driven
growth
aging
dlbcl
affects
develop
lymph
nodes
organs
may
either
localized
prognosis
relapsed
refractory
dlbcl
patients
poor
especially
factors
patients
refractory
dlbcl
curative
treatment
epcoritamab
epcoritamab
investigational
antibody
created
using
genmab
proprietary
duobody
technology
genmab
technology
designed
direct
cytotoxic
cells
selectively
tumors
elicit
immune
response
towards
malignant
cells
epcoritamab
designed
simultaneously
bind
cells
b
cells
induces
cell
mediated
killing
lymphoma
b
clinically
validated
therapeutic
target
expressed
many
malignancies
including
diffuse
large
lymphoma
follicular
lymphoma
mantle
cell
lymphoma
chronic
lymphocytic
epcoritamab
genmab
abbvie
part
companies
broad
oncology
collaboration
genmab
genmab
publicly
traded
international
biotechnology
company
specializing
creation
development
differentiated
antibody
therapeutics
treatment
cancer
founded
company
creator
following
approved
antibodies
daratumumab
agreement
janssen
biotech
treatment
certain
multiple
myeloma
indications
territories
including
europe
japan
subcutaneous
ofatumumab
agreement
novartis
ag
treatment
adults
relapsing
forms
multiple
sclerosis
teprotumumab
agreement
roche
granting
sublicense
horizon
therapeutics
plc
treatment
thyroid
eye
disease
subcutaneous
formulation
daratumumab
known
darzalex
daratumumab
approved
europe
treatment
adult
patients
certain
multiple
myeloma
indications
first
approved
genmab
created
therapy
ofatumumab
agreement
novartis
ag
approved
treatment
certain
chronic
lymphocytic
leukemia
indications
available
japan
also
available
territories
via
compassionate
use
oncology
access
programs
daratumumab
clinical
development
janssen
treatment
additional
multiple
myeloma
indications
blood
cancers
amyloidosis
genmab
also
broad
clinical
product
pipeline
genmab
technology
base
consists
validated
proprietary
next
generation
antibody
technologies
platform
generation
bispecific
antibodies
platform
creates
effector
function
enhanced
antibodies
platform
combines
two
acting
hexabody
molecules
introduce
selectivity
maximizing
therapeutic
potency
platform
enhances
potential
potency
bispecific
antibodies
hexamerization
company
intends
leverage
technologies
create
opportunities
full
future
products
genmab
alliances
top
tier
pharmaceutical
biotechnology
companies
genmab
headquartered
copenhagen
denmark
sites
utrecht
netherlands
princeton
new
jersey
tokyo
japan
contact
marisol
peron
corporate
vice
president
communications
investor
relations
e
mmp
investor
relations
andrew
carlsen
senior
director
investor
relations
e
acn
company
announcement
contains
forward
looking
statements
words
believe
expect
anticipate
intend
plan
similar
expressions
identify
forward
looking
statements
actual
results
performance
may
differ
materially
future
results
performance
expressed
implied
statements
important
factors
could
cause
actual
results
performance
differ
materially
include
among
others
risks
associated
clinical
development
products
uncertainties
related
outcome
conduct
clinical
trials
including
unforeseen
safety
issues
uncertainties
related
product
manufacturing
lack
market
acceptance
products
inability
manage
growth
competitive
environment
relation
business
area
markets
inability
attract
retain
suitably
qualified
personnel
unenforceability
lack
protection
patents
proprietary
rights
relationships
affiliated
entities
changes
developments
technology
may
render
products
technologies
obsolete
factors
discussion
risks
please
refer
risk
management
sections
genmab
recent
financial
reports
available
risk
factors
included
genmab
recent
annual
report
form
filings
securities
exchange
commission
sec
available
genmab
undertake
obligation
update
revise
forward
looking
statements
company
announcement
confirm
statements
reflect
subsequent
events
circumstances
date
made
relation
actual
results
unless
required
law
genmab
subsidiaries
following
trademarks
genmab
genmab
combination
genmab
duobody
combination
duobody
hexabody
combination
hexabody
trademarks
novartis
ag
affiliates
darzalex
trademarks
janssen
pharmaceutica
nv
trademark
horizon
therapeutics
plc
seer
https
statfacts
html
accessed
october
ries
et
al
seer
survival
monograph
cancer
survival
among
adults
seer
program
patient
tumor
characteristics
available
https
archive
publications
survival
accessed
october
american
cancer
society
types
lymphoma
available
https
cancer
accessed
august
lymphoma
research
foundation
diffuse
large
available
https
aboutlymphoma
nhl
dlbcl
accessed
august
crump
michael
et
al
outcomes
refractory
diffuse
large
lymphoma
results
international
blood
american
society
hematology
pmc
articles
engelbert
et
al
induces
potent
killing
malignant
b
cells
preclinical
models
provides
opportunities
subcutaneous
ebiomedicine
feb
doi
epub
jan
pmid
pmcid
sarwish
et
al
comparative
assessment
clinically
utilized
antibodies
chronic
lymphocytic
leukemia
cells
reveals
divergent
nk
cell
monocyte
macrophage
journal
immunology
baltimore
md
national
library
medicine
mar
pmc
articles
singh
vijay
et
al
development
novel
monoclonal
antibodies
modulation
levels
cell
surface
looking
improve
immunotherapy
journal
cancer
science
therapy
national
library
medicine
pmc
articles
company
announcement
cvr
lei
code
genmab
kalvebod
brygge
copenhagen
v
denmark
attachment
